NICE guidelines ration affordable osteoporosis drugs

December 11, 2009

Los Angeles, London, New Delhi, Singapore and Washington DC (December 11, 2009) - Low cost osteoporosis drugs are strictly rationed for the under 75s, and UK physicians hampered by restrictive guidelines, according to findings which appear today in the journal Therapeutic Advances in Musculoskeletal Disease, published by SAGE. A leading Cambridge University bone health expert has outlined flaws in NICE osteoporosis treatment guidance, which limits options for many postmenopausal women in the under-75 age bracket.

According to Cambridge University Professor of Bone Medicine, Juliet Compston, the current UK guidelines are unnecessarily complex. Physicians following the guidelines treat postmenopausal women aged over 75 with low trauma fractures (known as fragility fractures) with alendronate. This drug prevents further bone weakening by preventing the loss of bone that occurs with ageing.

However, physicians treating postmenopausal women under 75 with similar fractures have to demonstrate that the patient has bones scoring -2.5 or less on the 'T-score,' a measure of bone mass, to prescribe alendronate. There are alternatives for those who cannot take alendronate (etidronate, risedronate, or strontium ranelate or, for secondary prevention only, raloxifene) but a prescription for one of these often requires even more stringent criteria.

Alendronate, the first line of treatment, is available as a 'generic' drug and costs less than £20 per year to prescribe. With the second raft of treatments costing £350 per year or less, physicians are faced with a difficult ethical dilemma in patients who are intolerant to alendronate as they know that these treatments are effective, yet they often cannot prescribe them until the patient has lost more bone. This is particularly unfortunate since intolerance to alendronate is common in frail elderly women, who are at very high risk of suffering further fractures.

There are no current NICE guidelines for treating men with fractures, or either men or women treated with glucocorticoids, which are a common cause of osteoporosis. Without NICE guidelines, cash-strapped primary care organisations may chose not to extend treatment to these individuals.

Osteoporosis leads to over 1000 deaths each month in the UK alone from hip fractures, and costs the National Health Service (NHS) and UK government £2.3 billion each year, according to figures from the National Osteoporosis Society charity. Factors such as drinking three or more units of alcohol per day, a family history of osteoporosis and long-term rheumatoid arthritis are among those that can increase fracture risk.

The National Osteoporosis Guideline Group (NOGG) has produced alternative guidelines, using different criteria to NICE. Recent national guidelines from other countries are more in keeping with NOGG, which takes independent clinical risk factors into account for fracture prediction and uses the WHO-supported FRAX® fracture risk algorithm. The NOGG approach to second-line therapy also eliminates the additional criteria for those unable to tolerate alendronate.

NICE is an independent organisation, which produces guidance in several areas including NHS drug prescriptions, which in general the NHS has to adhere to. Although NICE guidelines are often key to ensuring the best and most cost-effective treatments, the technology appraisals for osteoporosis have "fallen below the normally high standards of NICE, resulting in outdated and inappropriately restrictive guidance," Compston argues, adding that when it comes to osteoporosis, "the fundamental principles of consistent use of the evidence base, transparency, and equity across disease states have not been observed."

Compston calls for a fresh NICE appraisal of osteoporosis treatments. A new appraisal may also benefit those beyond the UK - many other countries look to NICE guidelines as a template for their own national guidelines.
-end-
NICE: its influence in treating osteoporosis in the UK and beyond by Juliet Compston Is published today in Therapeutic Advances in Musculoskeletal Disease, published by SAGE. DOI: 10.1177/1759720X09354945. The paper will be free online for a limited period from http://tab.sagepub.com/cgi/reprint/1/2/63.

Author contact: Juliet Compston jec1001@cam.ac.uk

National Osteoporosis Society: www.nos.org.uk

NICE: http://www.nice.org.uk/

SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology and medicine. An independent company, SAGE has principal offices in Los Angeles, London, New Delhi, Singapore and Washington DC. www.sagepublications.com

SAGE Publications UK

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.